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While everybody is worrying about when the avian 
influenza A (H5N1) virus will adapt well enough in 
human to cause a pandemic, the emergence of a 
novel swine-origin influenza A (H1N1) virus (S-OIV) 
has shocked the world. On 29 April 2009, the World 
Health Organization raised the pandemic alert level 
from phase 4 to 5. As of 15 May, there have been 7503 
laboratory-confirmed cases of S-OIV infections and 65 
confirmed deaths globally, with more than 95% of the 
confirmed cases and all the deaths from the American 
continent. The S-OIV genome is made up of a unique 
combination of gene segments that had not been 
observed in previously known influenza A viruses as 
a result of genetic reassortment.
 The earliest evidence of influenza virus causing 
acute febrile respiratory illness in pigs can be traced 
to the 1930s.1 From the 1930s to the 1990s, classic 
swine influenza A (H1N1) was the commonest swine 
influenza virus circulating in the swine population. 
During these six decades, this virus did not undergo 
much genetic change. Sporadic cases of human 
infections due to swine influenza have been reported 
in the last four decades, of which most were caused by 
classic swine influenza A (H1N1) virus.2-6 Occupational 
exposure to pigs was the most important risk factor 
for infection.7,8 The clinical features of such infections 
were indistinguishable from those caused by human 
influenza viruses, although the mortality was higher.9 
At the end of the last century, multiple subtypes, 
including H1N1, H1N2 and H3N2, of triple-reassortant 
swine influenza A viruses emerged on the American 
continent.10,11 The genomes of these triple-reassortant 
viruses all contained combinations of swine, human 
and avian influenza virus gene segments. In the past 
few years of this century, sporadic cases of human 
infections caused by these triple-reassortant swine 
influenza A viruses have occurred on the American 
continent,12-15 mainly due to subtype H1N1.13 Most 
patients presented with fever and cough and all 
recovered, without resulting in efficient, sustained 
human-to-human transmission.12-15
 The first report on the clinical features of the 
642 confirmed cases of S-OIV infections in the United 
States showed that most patients presented with 
upper respiratory and systemic symptoms similar to 
those of seasonal influenza, the commonest being 
fever and cough, which were present in over 90% of 
the patients.16 The difference from seasonal influenza 
was that 25% of the patients had vomiting and 25% 
had diarrhoea.16 The age predilection reported could 
be due to outbreaks in schools, instead of inherent 
properties of the virus.16 Most infections were self-
limited; 9% of the patients were hospitalised and 
there were only two deaths.16 This is in line with an 
estimated case fatality rate of 0.4% for the epidemic 
in Mexico, which was calculated using a mathematical 
model pertaining to data on travellers.17 It is too 
early, however, to draw conclusions on the potential 
virulence of the virus, as the Spanish flu pandemic 
was also mild initially in the spring of 1918, but the 
virus became more virulent during the second wave 
of infection in winter.18 The present S-OIV differs 
from the triple-reassortant swine influenza A virus 
(subtype H1N1) associated with sporadic infections, 
by virtue of acquiring two gene segments (NA and M) 
from the Eurasian swine lineage.16 The other six gene 
segments (PB2, PB1, PA, HA, NP, and NS) were similar 
to those of the triple-reassortant swine influenza A 
virus reported hitherto.16 The first confirmed case of S-
OIV infection in Hong Kong also presented with fever, 
cough, and myalgia.19 The diagnosis was confirmed 
by an ultra-rapid reverse-transcriptase-polymerase-
chain-reaction assay, which specifically detects S-OIV 
but not circulating human influenza H1N1 or H3N2 
viruses, with the result available in 50 minutes.19 This 
enabled rapid isolation of the patient and quarantine 
of contacts. The viral load in the nasopharyngeal 
secretion of the patient was in the range of 106 to 107 
copies per mL during the first 3 days of the illness, but 
decreased to undetectable level by the sixth day.19
 A major concern is the possibility that S-OIV 
will acquire resistance to antivirals as the epidemic 
evolves. The two classes of antiviral agents against 
influenza viruses are the adamantanes, which include 
amantadine and rimantadine, and the neuraminidase 
inhibitors, which include oseltamivir and zanamivir. 
The M gene encodes the target of the adamantanes. 
So far, all strains of S-OIV from the current epidemic 
contain a serine®asparagine mutation at codon 
31 of this gene, which confers resistance to both 
amantadine and rimantadine.16 This mutation is 
also highly prevalent among circulating subtypes of 
European swine influenza A viruses.20 Fortunately, all 
strains of S-OIV tested so far are susceptible to both 
oseltamivir and zanamivir, which would be the main 
stay of treatment for this virus at the moment.16 This is 
in contrast to the situation in the 2008-2009 influenza 
season, in which most circulating influenza A (H1N1) 
viruses were apparently resistant to oseltamivir though 
still susceptible to zanamivir.21,22 However, massive use 
of these antiviral agents for treatment and prophylaxis, 
may lead to development of resistance, which would 
pose a challenge to the management of patients 
severely compromised by these infections and result 
in increased mortality.
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 It seems that the S-OIV vaccine is the answer 
to this infection. Nevertheless, there are still many 
questions to answer and dilemmas to resolve, given 
that the infection appears mild at the moment. 
Should companies stop the production of seasonal 
influenza vaccine and focus on S-OIV vaccine? How 
can we ensure a fair distribution of the vaccine? Are 
two shots required for adequate protection against 
this new virus with antigenic shift? Will S-OIV vaccine 
be associated with similar profiles of side-effects, 
in particular, Guillain-Barré syndrome, as seasonal 
influenza vaccine? These issues have to be addressed 
before determining the most reasonable vaccine 
policy.
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